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Objective. To compare the efficacy and safety of
subcutaneous (SC) and intravenous (IV) abatacept.
Methods. In this phase IIIb double-blind, double-
dummy, 6-month study, patients with rheumatoid ar-
thritis (RA) and inadequate responses to methotrexate
were randomized to receive 125 mg SC abatacept on
days 1 and 8 and weekly thereafter (plus an IV loading
dose [10 mg/kg] on day 1) or IV abatacept (10
mg/kg) on days 1, 15, and 29 and every 4 weeks
thereafter. The primary end point for determining the
noninferiority of SC abatacept to IV abatacept was the
proportion of patients in each group meeting the Amer-
ican College of Rheumatology 20% improvement criteria
(achieving an ACR20 response) at month 6. Other
efficacy end points, immunogenicity, and safety were
also assessed.
Results. Of 1,457 patients, 693 of 736 (94.2%)
treated with SC abatacept and 676 of 721 (93.8%)
treated with IV abatacept completed 6 months. At
month 6, 76.0% (95% confidence interval 72.9, 79.2) of
SC abatacept–treated patients versus 75.8% (95% con-
fidence interval 72.6, 79.0) of IV abatacept–treated
patients achieved an ACR20 response (estimated differ-
ence between groups 0.3% [95% confidence interval
–4.2, 4.8]), confirming noninferiority of SC abatacept to
IV abatacept. Onset and magnitude of ACR responses
and disease activity and physical function improve-
ments were comparable between the SC and IV
abatacept–treated groups. The proportions of adverse
events (AEs) and serious AEs over 6 months were 67.0%
and 4.2%, respectively, in the SC abatacept–treated
group and 65.2% and 4.9%, respectively, in the IV
abatacept–treated group, with comparable frequencies
of serious infections, malignancies, and autoimmune
events between groups. SC injection site reactions
(mostly mild) occurred in 19 SC abatacept (IV
placebo)–treated patients (2.6%) and 18 IV abatacept
(SC placebo)–treated patients (2.5%). Abatacept-induced
antibodies occurred in 1.1% of SC abatacept–treated
patients and 2.3% of IV abatacept–treated patients.
ClinicalTrials.gov identifier: NCT00559585.
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2854Conclusion. SC abatacept provides efficacy and
safety comparable with that of IV abatacept, with low
immunogenicity and high retention rates, consistent
with the established IV abatacept profile. Rates of
injection site reactions were low. SC abatacept will
provide additional treatment options, such as an alter-
native route of administration, for patients with RA.
The first biologic therapies were approved for the
treatment of rheumatoid arthritis (RA) more than a
decade ago (1); since then, a variety of agents with
differing mechanisms of action have been approved.
Many factors influence the selection of an appropriate
RA therapy. Most importantly, safety and efficacy must
be considered in the context of the patient’s clinical
profile; however, the route of administration of the
agent can also be a determining factor.
The efficacy and safety of abatacept, a selective T
cell costimulation modulator, have been established
across a range of RA patient populations (2–9). Cur-
rently, abatacept is approved for monthly intravenous
(IV) administration according to a weight-tiered dosing
regimen in patients with moderate-to-severe RA (10).
The availability of a subcutaneous (SC) formulation of
abatacept would increase the treatment options avail-
able to patients with RA, particularly those wishing to
self-administer their therapy.
An SC formulation of abatacept has been studied
in multiple phase II and III trials. SC abatacept admin-
istered at a fixed dose of 125 mg/week was well tolerated
over 3 months, with a safety and immunogenicity profile
similar to that of the IV regimen (10 mg/kg monthly)
(11,12). In the phase IIIb ACCOMPANY (Abatacept in
Subjects with Rheumatoid Arthritis Administered Plus
or Minus Background Methotrexate Subcutaneously)
study, SC abatacept demonstrated acceptable tolerabil-
ity with minimal injection site reactions and low rates of
immunogenicity when administered as a monotherapy,
or with background methotrexate (MTX), even in the
absence of an IV loading dose (13,14). Improvements in
disease activity were observed across all SC treatment
groups (13,14). Here we report the outcome of the
multinational, phase IIIb, noninferiority ACQUIRE
(Abatacept Comparison of Subcutaneous versus Intra-
venous in Inadequate Responders to Methotrexate)
study, which directly compared the efficacy and safety of
SC abatacept with IV abatacept.
PATIENTS AND METHODS
Patient population. Patients who met the American
College of Rheumatology (ACR) 1987 revised criteria for the
classification of RA (15) who were in functional classes I, II,
or III according to the ACR 1991 revised criteria (16) and
who had active disease were eligible for inclusion. Patients
had to have had an inadequate response to 3 months
of MTX therapy (15 mg/week), with 10 swollen joints, 12
tender joints, and C-reactive protein (CRP) levels of
0.8 mg/dl at randomization. Patients were screened for
tuberculosis (TB) at baseline and excluded if there was current
clinical/radiographic/laboratory evidence of active TB or a
history of active TB within the last 3 years, even if treated.
Patients with a history of active TB 3 years earlier were
included only with documentation of appropriate treatment.
Patients with latent TB were included if treatment with
isoniazid (9-month course) had been initiated at least 4 weeks
prior to receiving study drug and if active infection was ruled
out by negative chest radiographic findings at enrollment.
Study design. This was a 6-month, multinational, phase
IIIb, randomized, double-blind, double-dummy study (17),
with an open-label long-term extension period (results to be
presented separately). The protocol and patients’ informed
consent received Institutional Review Board/Independent Eth-
ics Committee approval. The study was conducted in accor-
dance with the Declaration of Helsinki and was consistent with
the International Conference on Harmonization and Good
Clinical Practice.
Patients were randomized (1:1), with stratification by
body weight (60 kg, 60–100 kg, 100 kg), to receive abata-
cept either by SC injections (125 mg) on days 1 and 8 and
weekly thereafter or by IV infusions (10 mg/kg based on
weight range) on days 1, 15, and 29 and every 4 weeks
thereafter. Patients randomized to SC abatacept also received
an IV abatacept loading dose (10 mg/kg based on weight
range) on day 1, to ensure that the trough serum concentration
of abatacept required to achieve full receptor occupancy, and
thus maximal T cell inhibition (i.e., 10 g/ml) (11,12,18), was
achieved as quickly as possible.
A double-dummy design was used to maintain blind-
ing. Patients randomized to the SC abatacept group received
IV placebo on days 15 and 29 and every 4 weeks thereafter,
and patients randomized to the IV abatacept group received
SC placebo on day 8 and weekly thereafter. For all patients, SC
injection was administered 30 minutes after the end of IV
infusion. Patients and study site personnel remained blinded
with regard to treatment assignments during the double-blind
period.
Patients continued taking MTX at the same dosage
they were receiving at randomization (minimum 15 mg/week),
and changes were not permitted during the first 6 months
(except if toxicity occurred). All other disease-modifying anti-
rheumatic drugs were discontinued at least 4 weeks prior to
study treatment (or 8 weeks for leflunomide). Low-dose oral
corticosteroids (10 mg/day prednisone equivalent) were per-
mitted throughout the trial; the dosage had to be stable for
25–28 days prior to study entry. A maximum of 2 of the
following high-dose corticosteroid courses were permitted, as
long as they were not within 28 days of the month 6 visit: a
short (maximum 2 weeks) oral course of high-dose cortico-
steroids, a single intramuscular (IM) dose of corticosteroids, or
a single intraarticular (IA) injection of corticosteroids (any
joint that received an IA injection was counted as having
“active” disease for the remainder of the study).
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formed on days 1, 15, and 29 and then every 4 weeks
thereafter. The primary end point for determining the nonin-
feriority of SC abatacept to IV abatacept was the proportion
of patients in each group meeting the ACR 20% improvement
criteria (achieving an ACR20 response) (19) at month 6.
The proportions of patients achieving ACR50 and ACR70
responses at month 6 were secondary end points. Subgroup
analyses (prespecified) are also presented for ACR responses
according to patient weight range (60 kg, 60–100 kg,
100 kg).
Physical function, measured using the patient-reported
Health Assessment Questionnaire disability index (HAQ DI)
(20), was a secondary end point. The Disease Activity Score in
28 joints (DAS28) (21) using the CRP level (DAS28-CRP) was
a tertiary end point. Mean changes in HAQ DI score and
DAS28-CRP at month 6 are summarized. The proportions of
patients achieving a HAQ DI response (improvement of 0.3
units from baseline) (22), a low disease activity state (DAS28-
CRP of 3.2), and DAS28-defined remission (DAS28-CRP of
2.6) are summarized. Additional patient-reported outcomes,
such as pain and global assessment of disease activity (assessed
using a 0–100-mm visual analog scale), are reported.
Safety and immunogenicity assessments. Safety as-
sessments were classified using the Medical Dictionary for
Regulatory Activities (MedDRA). Patients were monitored for
SC injection site reactions and for acute infusion reactions
(within 1 hour of the start of IV infusion). Injection site and
infusion reactions were prespecified, based on a list of Med-
DRA Preferred Terms. Autoimmune events were also pre-
specified based on a list of MedDRA Preferred Terms.
Blood samples for immunogenicity assessments were
collected prior to abatacept administration on day 1 and at
months 3 and 6. The primary analysis method for detection
of antiabatacept and anti–cytotoxic T lymphocyte–associated
protein 4 Tip (anti–CTLA-4-T; the abatacept molecule without
the Ig portion) antibodies was a validated enzyme-linked
immunosorbent assay. An electrochemiluminescence assay
(Meso-Scale Discovery) was used as a secondary assay for the
assessment of immunogenicity.
Statistical analysis. The noninferiority margin for 70%
preservation of the minimum effect of IV abatacept was 7.5%
([1  0.7]  25%), based on a minimum expected ACR20
response benefit of IV abatacept 25% greater than that of
placebo (7,23). If the lower boundary of the 2-sided 95%
confidence interval (95% CI) of the difference between SC
abatacept and IV abatacept is at least 7.5%, SC abatacept
can be considered noninferior to IV abatacept. This allows for
a maximum difference of –2.1% (95% CI –7.5, 3.2) between
the ACR20 response to SC abatacept and that to IV abatacept.
A sample size of 1,440 was calculated to provide 80% power
to demonstrate that the lower limit of the 2-sided 95% CI of
the difference in ACR20 response rates between SC abatacept
and IV abatacept was at least –7.5%.
Efficacy data were assessed for both the per-protocol
and the intent-to-treat (ITT) populations. The ITT population
includes all randomized patients who received at least 1 dose
of medication; the per-protocol population excludes patients
with protocol violations. Results from 1 investigating site were
excluded from efficacy analyses owing to noncompliance with
good clinical practice (8 patients), but were included in all
safety analyses. Based on regulatory guidance, the per-
protocol population was the primary analysis set for the
primary end point; ACR responses over time were analyzed
for both the per-protocol and ITT populations. Data are
presented for the ITT population unless stated otherwise.
Safety data are presented for all patients who received at least
1 dose of study medication.
Baseline demographics and clinical characteristics
were analyzed descriptively for all patients. Treatment differ-
ences were calculated for efficacy assessments, with 95% CIs.
For ACR or HAQ DI responses, patients who discontinued
were considered nonresponders. For mean change in HAQ DI,
DAS28-CRP, and patient-reported outcomes, missing values
were imputed using a last observation carried forward analysis
(we excluded patients for whom only baseline observations
Figure 1. Patient disposition over 6 months (intent-to-treat population). SC  subcutaneous;
IV  intravenous.
2856 GENOVESE ET ALwere available). For low disease activity state or DAS28-
defined remission, we included patients for whom data were
available at the visit of interest (as-observed analysis). Changes
in HAQ DI score and DAS28-CRP were assessed using
analysis of covariance (which included treatment as the main
factor and baseline values and weight stratification as covari-
ates), adjusted mean  SEM, and 95% CI for adjusted mean
difference between treatment groups.
RESULTS
Patient disposition. A total of 1,457 patients were
randomized and treated with abatacept plus MTX; 736
were treated with SC abatacept plus IV placebo and 721
were treated with IV abatacept plus SC placebo (Figure
1). Of these randomized and treated patients, 40 (5.4%)
in the SC abatacept–treated group and 38 (5.3%) in the
IV abatacept–treated group had at least 1 relevant
protocol deviation. The most frequent protocol devia-
tions were joint count of 10 swollen joints or 12
tender joints at randomization, CRP level 0.5 mg/dl
prior to or on day 1, or IA/IM/IV steroid injections or
high oral steroid bursts (defined as oral steroid use
10 mg prednisone equivalent for more than 14 days)
within 28 days prior to the month 6 assessment. Over
6 months, 43 SC abatacept–treated patients (5.8%) and
Table 1. Baseline demographics and clinical characteristics, and permitted concomitant medications*













Age, years 49.9  13.0 49.9  12.7 49.9  13.2 50.1  12.6
Weight, kg 72.1  18.1 71.5  17.5 72.0  18.0 71.8  17.6
Weight group, no. (%)
60 kg 175 (25.1) 171 (25.0) 186 (25.3) 179 (24.8)
60–100 kg 464 (66.7) 465 (68.1) 492 (66.8) 489 (67.8)
100 kg 57 (8.2) 47 (6.9) 58 (7.9) 53 (7.4)
Women, % 84.2 80.4 84.4 80.4
Caucasian, % 74.1 73.9 74.7 74.5
Disease duration, years 7.6  8.0 7.7  7.9 7.6  8.1 7.7  7.8
Tender joints 30.0  14.1 29.2  13.1 30.1  14.1 29.1  13.3
Swollen joints 20.5  9.4 19.6  8.5 20.4  9.6 19.4  8.6
HAQ DI score 1.7  0.7 1.7  0.7 1.7  0.7 1.7  0.7
Patient’s assessment of pain, 0–100-mm VAS 68  20.0 66.9  20.5 67.8  20.1 66.8  20.5
Patient’s global assessment of disease activity, 0–100-mm VAS 67.2  20.1 65.2  19.9 66.8  20.4 64.9  20.0
Physician’s global assessment of disease activity, 0–100-mm VAS 64.3  16.5 63.4  16.3 64.3  16.5 63.1  16.6
CRP level, mg/dl 2.7  2.9† 2.7  2.9 2.6  2.9‡ 2.7  2.9
DAS28-CRP 6.25  0.84§ 6.22  0.83 6.23  0.85¶ 6.20  0.84
Rheumatoid factor positive, no. (%) 582 (85.1) 583 (86.5) 614 (84.8) 611 (85.9)
MTX dose, mg/week 16.3  3.6 16.5  3.7 16.3  3.6 16.5  3.8
Biologic therapy prior to enrollment, no. (%)
Biologics 24 (3.4) 31 (4.5) 32 (4.3) 43 (6.0)
Anti-TNF therapy 23 (3.3) 31 (4.5) 31 (4.2) 43 (6.0)
Etanercept 12 (1.7) 10 (1.5) 17 (2.3) 18 (2.5)
Adalimumab 5 (0.7) 11 (1.6) 9 (1.2) 14 (1.9)
Infliximab 6 (0.9) 10 (1.5) 11 (1.5) 17 (2.4)
Anakinra 1 (0.1) 0 1 (0.1) 2 (0.3)
Tocilizumab 0 1 (0.1) 0 1 (0.1)
Concomitant medication over the 6-month study period#
Corticosteroids (oral and/or injectable), no. (%) 500 (71.8) 508 (74.4) 531 (72.1) 538 (74.6)
Oral corticosteroid dose, mg/day 4.7  4.4 5.1  7.0 4.8  4.5 5.2  6.9
High-dose corticosteroids, no. (%)
1 8 (1.1) 7 (1.0) 10 (1.4) 12 (1.7)
2 IA injections 3 (0.4) 2 (0.3) 4 (0.5) 7 (1.0)
* Except where indicated otherwise, values are the mean  SD. SC  subcutaneous; MTX  methotrexate; IV  intravenous; ITT  intent-to-treat;
HAQ DI  Health Assessment Questionnaire disability index; VAS  visual analog scale; CRP  C-reactive protein; DAS28-CRP  Disease





# Includes data from up to 56 days after the last dose of study drug.
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the study; 693 SC abatacept–treated patients (94.2%)
and 676 IV abatacept–treated patients (93.8%) were still
participating in the study at month 6 (Figure 1).
Baseline demographics and clinical characteris-
tics. Baseline demographics and clinical characteristics
were similar across the SC and IV abatacept–treated
Figure 2. Proportions of SC or IV abatacept–treated patients meeting
the American College of Rheumatology 20% improvement criteria
(achieving an ACR20 response) over 6 months, as well as proportions
of patients achieving ACR50 or ACR70 responses during the same
time period. A, ACR20 (top), ACR50 (middle), and ACR70 (bottom)
responses over 6 months for the per-protocol (PP) population (n  693
in the SC abatacept–treated group, n  678 in the IV abatacept–
treated group). B, ACR20 (top), ACR50 (middle), and ACR70
(bottom) responses over 6 months for the intent-to-treat (ITT) popu-
lation (n  733 in the SC abatacept–treated group, n  716 in the IV
abatacept–treated group). C, ACR20 responses at month 6 by weight
category for the ITT population (n  733 in the SC abatacept–treated
group, n  716 in the IV abatacept–treated group). Not included are
data on 8 patients who were excluded from all efficacy analyses owing
to site noncompliance with study procedures. Asterisks indicate dos-
ages corresponding to 10 mg/kg, according to weight range. Error
bars represent 95% confidence intervals. See Figure 1 for other
definitions.
Figure 3. Functional disability and disease activity over 6 months in
SC or IV abatacept–treated patients (intent-to-treat [ITT] popula-
tion). A, Health Assessment Questionnaire (HAQ) disability index
response (improvement of 0.3 units from baseline) over 6 months. B,
Low disease activity state (LDAS) (Disease Activity Score in 28 joints
using the C-reactive protein level [DAS28-CRP] of 3.2) (top) and
DAS28-defined remission (DAS28-CRP of 2.6) (bottom) over 6
months (as-observed analysis). Not included are data on 8 patients who
were excluded from all efficacy analyses owing to site noncompliance
with study procedures. Error bars represent 95% confidence intervals.
See Figure 1 for other definitions.
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populations (Table 1). In the SC and IV abatacept–
treated groups, the mean RA duration was 7.6 and 7.7
years, respectively, while the mean tender and swollen
joint counts were 30.1 and 20.4, respectively, for the SC
abatacept–treated group and 29.1 and 19.4, respectively,
for the IV abatacept–treated group (ITT population)
(Table 1).
Permitted concomitant medications. All patients
received MTX, and the mean baseline dose was compa-
rable between groups (Table 1). The proportion of
patients receiving concomitant corticosteroids over 6
months was 72.1% in the SC abatacept–treated group
and 74.6% in the IV abatacept–treated group (ITT
population) (Table 1). High-dose corticosteroid use was
infrequent and comparable between groups; 10 patients
(1.4%) and 12 patients (1.7%) in the SC and IV
abatacept–treated groups, respectively, received at least
1 high-dose oral, IM, or IV corticosteroid treatment
(ITT population) (Table 1).
Clinical efficacy. ACR responses. The study met
the primary objective of showing noninferiority of SC
abatacept to IV abatacept. The proportion of patients
achieving an ACR20 response at month 6 (primary end
point; per-protocol population) was 76.0% (95% CI
72.9, 79.2) for the SC abatacept–treated group and
75.8% (95% CI 72.6, 79.0) for the IV abatacept–treated
group (Figure 2A); the estimate of difference between
groups was 0.3% (95% CI –4.2, 4.8). ACR50 and
ACR70 response rates over 6 months were also compa-
rable between the SC and IV abatacept–treated groups
(per-protocol population) (Figure 2A). ACR20, ACR50,
and ACR70 response rates over 6 months were compa-
rable between the SC and IV abatacept–treated groups
in the ITT population, and were similar to those in the
per-protocol population (Figures 2A and B). The esti-
mate of difference between the SC and IV abatacept–
treated groups for the ACR20 response was 0.5% (95%
CI –4.0, 4.9) (ITT population) (Figure 2B). ACR20,
ACR50, and ACR70 response rates continued to in-
crease over 6 months (Figure 2). When the primary end
point (ACR20 response at month 6) was analyzed by
weight, comparable results were observed between the
SC and IV abatacept–treated groups (Figure 2C).
Physical function. Improvements in HAQ DI
score were comparable between the SC and IV
abatacept–treated groups. The proportion of HAQ DI
responders was 68.2% (95% CI 64.8, 71.6) for the SC
abatacept–treated group and 63.8% (95% CI 60.3, 67.3)
for the IV abatacept–treated group at month 6 (estimate
of difference 4.5% [95% CI –0.4, 9.4]) (Figure 3A). The
adjusted mean  SEM change from baseline to month 6
in HAQ DI scores was –0.69  0.02 and –0.70  0.02 in
the SC and IV abatacept–treated groups, respectively.
Disease activity. The mean  SD baseline
DAS28-CRP was similar in the SC and IV abatacept–
treated groups (Table 1). At month 6, the mean  SD
DAS28-CRP was 3.7  1.3 in both the SC and IV
abatacept–treated groups, representing adjusted
mean  SEM improvements from baseline of –2.57 
0.05 and –2.55  0.05, respectively.
At month 6, 39.5% (95% CI 35.8, 43.1) and
41.3% (95% CI 37.6, 45.1) of patients in the SC and IV
abatacept–treated groups, respectively, had achieved a
low disease activity state, and 24.2% (95% CI 20.9, 27.4)
and 24.8% (95% CI 21.5, 28.1), respectively, had
achieved DAS28-defined remission (Figure 3B). The
estimates of treatment difference between the SC and
IV abatacept–treated groups were 1.9% (95% CI
7.2, 3.4) and 0.7% (95% CI 5.3, 4.0) for low disease
activity state and DAS28-defined remission, respec-
tively.
Patient’s assessment of pain and disease activity. At
month 6, the adjusted mean  SEM percent improve-
ment from baseline in pain was 49.1  1.74% and 44.9 







Deaths 2 (0.3) 5 (0.7)
Serious AEs 31 (4.2) 35 (4.9)
Discontinued due to serious AEs 8 (1.1) 14 (1.9)
AEs 493 (67.0) 470 (65.2)
Discontinued due to AE 15 (2.0) 25 (3.5)
Infections 234 (31.8) 221 (30.7)
Serious infections 5 (0.7) 10 (1.4)
Malignancies 3 (0.4) 5 (0.7)
Autoimmune events 7 (1.0) 6 (0.8)
SC injection site reactions 19 (2.6) 18 (2.5)
Hematoma 4 (0.5) 4 (0.6)
Pruritus 6 (0.8) 1 (0.1)
Erythema 5 (0.7) 1 (0.1)
Pain 1 (0.1) 4 (0.6)
Papule 1 (0.1) 3 (0.4)
Reaction 1 (0.1) 3 (0.4)
Rash 2 (0.3) 1 (0.1)
Urticaria 0 2 (0.3)
Other† 4 (0.5) 0
* Values are the number (%) of events. Safety data are based on all
patients who received at least 1 dose of abatacept. Given the double-
dummy study design, patients in the SC abatacept–treated group
received IV placebo and patients in the IV abatacept–treated group
received SC placebo. AEs  adverse events (see Table 1 for other
definitions).
† Individual SC injection site reactions not reported in more than 1
patient overall.
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respectively (adjusted difference from IV 4.2% [95% CI
–0.7, 9.1]). For patient’s global assessment of disease
activity, the adjusted mean  SEM percent improve-
ment from baseline was 48.1  1.66% and 47.4  1.68%
in the SC and IV abatacept–treated groups, respectively,
at month 6 (adjusted difference from IV 0.7% [95% CI
–3.9, 5.4]).
Safety. The safety profile observed with SC
abatacept was generally comparable to that with IV
abatacept (Table 2). The proportions of adverse events
(AEs) and serious AEs were 67.0% and 4.2%, respec-
tively, in the SC abatacept–treated group and 65.2% and
4.9%, respectively, in the IV abatacept–treated group.
The AEs reported in 5% of patients in either the SC or
IV abatacept–treated group were headache, nasophar-
yngitis, upper respiratory tract infection, diarrhea, and
nausea. Discontinuations due to serious AEs occurred in
1.1% of the SC abatacept–treated patients and in 1.9%
of the IV abatacept–treated patients; these differences
were primarily driven by infections. No patients discon-
tinued due to serious infections in the SC abatacept–
treated group, while 4 patients (0.6%) discontinued in
the IV abatacept–treated group.
Two and 5 deaths were reported in the SC and IV
abatacept–treated groups, respectively. In the SC
abatacept–treated group, these resulted from staphylo-
coccal septicemia in one patient and an unknown cause
in another patient (who had a prior history of heavy
smoking and frequent alcohol use). The 5 deaths in the
IV abatacept–treated group resulted from subarachnoid
hemorrhage, adenocarcinoma of the gall bladder with
metastases, necrotizing pneumonia, bowel infarction,
and multiple organ failure with septic shock and lung
sepsis.
Infections. The frequency of infections was com-
parable between the SC and IV abatacept–treated
groups, with most events being mild or moderate in
intensity. The most frequently reported infections were
nasopharyngitis (5.6% and 5.8%), upper respiratory
tract infection (4.8% and 5.1%), bronchitis (3.4% and
4.0%), urinary tract infection (2.9% and 2.6%), and
pharyngitis (2.6% and 1.8%) in the SC and IV
abatacept–treated groups, respectively.
Serious infections occurred in 5 patients (0.7%)
in the SC abatacept–treated group and 10 patients
(1.4%) in the IV abatacept–treated group. The most
frequently reported serious infections were pneumonia
(1 patient [0.1%] in the SC abatacept–treated group and
3 patients [0.4%] in the IV abatacept–treated group),
gastroenteritis (1 patient [0.1%] in each group), and
urinary tract infection (2 patients [0.3%] in the IV
abatacept–treated group); all other serious infections
occurred in only 1 patient overall. There were no
opportunistic infections, including TB, in either treat-
ment group.
Malignancies. Malignancies occurred in 3 patients
(0.4%) in the SC abatacept–treated group (basal cell
carcinoma in 2 patients and B cell lymphoma in 1
patient) and 5 patients (0.7%) in the IV abatacept–
treated group (basal cell carcinoma, cervix carcinoma
[stage 0], colon neoplasm, metastatic gall bladder can-
cer, and squamous cell carcinoma of the skin in 1 patient
each).
Autoimmune events. Prespecified autoimmune
events were reported in 1% of patients in each treat-
ment arm (7 patients [1.0%] and 6 patients [0.8%] in the
SC and IV abatacept–treated groups, respectively); all
were mild or moderate in intensity. The most frequently
reported autoimmune event was psoriasis (2 patients
[0.3%] in the SC abatacept–treated group and 4 patients
[0.6%] in the IV abatacept–treated group). Other auto-
immune events reported in the SC abatacept–treated
group were erythema nodosum, episcleritis, uveitis, Ray-
naud’s syndrome, and Sjo ¨gren’s syndrome (in 1 patient
each); other autoimmune events reported in the IV
abatacept–treated group were hyperthyroidism and
Crohn’s disease (in 1 patient each). The patient with
Crohn’s disease subsequently discontinued from the
study; no other autoimmune event resulted in discontin-
uation or interruption of treatment.
Infusion- and injection-related events. Prespecified
SC injection site reactions were reported in 19 patients
(2.6%) in the SC abatacept–treated group and in 18
patients (2.5%) in the IV abatacept (SC placebo)–
treated group (Table 2). All SC injection site reactions
were mild (89.2%) or moderate (10.8%) in intensity, and
none resulted in withdrawal from the study. The most
frequently reported events in the SC and IV abatacept–
treated groups, respectively, were pruritis (6 patients
[0.8%] and 1 patient [0.1%]), erythema (5 patients
[0.7%] and 1 patient [0.1%]), and hematoma (4 pa-
tients each [0.5% and 0.6%, respectively]). Pain at the
injection site was rare (1 patient [0.1%] in the SC
abatacept–treated group and 4 patients [0.6%] in the IV
abatacept [SC placebo]–treated group).
Acute infusional events (occurring within 1 hour
of the start of the IV infusion) were reported in 20
patients (2.7%) in the SC abatacept (IV placebo)–
treated group. The majority of patients (n  12) expe-
rienced events on day 1, after the IV abatacept loading
dose, with the remaining patients (n  8) experiencing
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events were reported in 16 patients (2.2%) in the IV
abatacept–treated group. The types of acute infusional
events were similar in the SC and IV abatacept–treated
groups. Events were mostly mild or moderate in inten-
sity, and the most common events were urticaria (3 pa-
tients [0.4%] and 2 patients [0.3%] in the SC and IV
abatacept–treated groups, respectively), nausea (2 pa-
tients [0.3%] in each group), headache (2 patients
[0.3%] in each group), and increased blood pressure
(3 patients [0.4%] and 1 patient [0.1%] in the SC and IV
abatacept–treated groups, respectively).
One patient (0.1%) in each group had an ana-
phylactic reaction on day 1. The patient in the SC
abatacept–treated group was reported to develop grade
II anaphylaxis (moderate in intensity) with grade III skin
rashes, a cough, hypotension, and tachycardia, subse-
quent to receiving the IV abatacept loading dose. The
patient in the IV abatacept–treated group experienced
grade III anaphylaxis (severe in intensity) with pruritus,
dizziness, nausea, diaphoresis, eyelid edema, and a rash
on the face and thorax. For both patients, the events
resolved on day 2, and no further doses of abatacept
were administered.
Immunogenicity. In total, 3 patients (0.4%) and
5 patients (0.7%) tested seropositive for antiabatacept
antibodies in the SC and IV abatacept–treated groups,
respectively (Table 3). A total of 5 patients (0.7%) and
11 patients (1.5%) tested seropositive for anti–CTLA-
4-T antibodies in the SC and IV abatacept–treated
groups, respectively (Table 3). The presence of a posi-
tive antibody seroconversion did not appear to affect the
efficacy or safety of abatacept (data not shown).
DISCUSSION
A variety of biologic agents that are administered
either via the SC route or via the IV route are now
available for the treatment of RA. The T cell costimu-
lation modulator, abatacept, is approved for IV admin-
istration, and the long-term efficacy and safety profile of
IV abatacept in patients with an inadequate response to
MTX is well established (8,9,24). The availability of an
alternative formulation of abatacept for administration
via the SC route would increase the treatment options
for patients with RA.
To investigate the clinical profile of an SC for-
mulation of abatacept, a noninferiority study was con-
ducted in patients with moderate-to-severe RA with
inadequate MTX response. The aim of this study was to
demonstrate whether the efficacy of SC abatacept is
comparable with that of IV abatacept. Based on guide-
lines and feedback from regulatory authorities (25–27),
assessment of noninferiority of SC abatacept to IV
abatacept can be demonstrated by a 70% preservation of
the treatment effect (measured by the ACR20 re-
sponse). This predefined stringent noninferiority margin
translates into an allowable absolute maximum differ-
ence of –2.1% between SC abatacept and IV abatacept.
Based on regulatory statistical guidance (26), a per-
protocol population was used for the primary end point.
This population is considered more conservative for
study in noninferiority trials, since it excludes patients
with protocol violations and is therefore more likely to
reflect differences between treatment arms (28).
Results presented here demonstrate an estimate
of difference of 0.3% between treatment groups in the
per-protocol population, confirming noninferiority of
SC abatacept to IV abatacept. Approximately three-
fourths of patients achieved an ACR20 response by
month 6 in both groups. The rate and magnitude of
response were comparable between SC abatacept and
IV abatacept, demonstrated by ACR responses and
improvements in physical function, disease activity,
and patient-assessed outcomes. These efficacy benefits
confirm those from the phase IIIb ACCOMPANY study
of SC abatacept (13,14).
The SC formulation of abatacept is administered
as a fixed dose (125 mg) across all weight ranges. This
approach has previously been investigated in a phase II
trial, which demonstrated that, across a range of weight
groups, SC fixed dosing of 125 mg/week (plus an IV
loading dose of 10 mg/kg on day 1) resulted in median
trough serum concentrations comparable to or higher
than those observed with the approved IV weight-tiered
dosing regimen (11,12) and above the minimum concen-
tration predicted to exert maximal T cell inhibition (29).
Importantly, in the current trial, CIs for ACR20 re-
sponses overlap between the weight categories in the SC
Table 3. Immunogenicity rate (ITT population)*
Antiabatacept Anti–CTLA-4-T Total
SC
Treatment visit 3/707 (0.4) 2/716 (0.3) 5/716 (0.7)
Posttreatment visit† 0/26 3/28 (10.7) 3/28 (10.7)
Overall 3/714 (0.4) 5/725 (0.7) 8/725 (1.1)
IV
Treatment visit 5/691 (0.7) 4/702 (0.6) 9/702 (1.3)
Posttreatment visit† 0/29 7/31 (22.6) 7/31 (22.6)
Overall 5/698 (0.7) 11/710 (1.5) 16/710 (2.3)
* Values are the number/total number (%) of patients. Data are based
on patients for whom immunogenicity assessments were available.
Anti–CTLA-4-T  anti–cytotoxic T lymphocyte–associated protein 4
Tip (see Table 1 for other definitions).
† Assessed for up to 85 days after withdrawal from the study.
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fits are generally comparable across weight ranges.
ACR20 response rates were comparable between the SC
and IV abatacept–treated groups within each weight
category, although rates in both treatment groups were
numerically lower in the 100 kg weight group than in
the other 2 groups (60 kg and 60–100 kg).
The safety observed with SC abatacept in this
6-month study was consistent with that found in previous
phase IIIb SC abatacept studies (13,14) and studies of
long-term IV administration. No new clinically signifi-
cant AEs were observed, and safety was generally com-
parable to that of IV abatacept, for which there are now
12,000 cumulative patient-years of exposure in 4,419
patients (30). Similar frequencies of AEs, serious AEs,
infections, malignancies, and autoimmune events were
reported in the SC and IV abatacept–treated groups.
Discontinuations due to serious AEs were slightly less
frequent in the SC abatacept–treated group than in the
IV abatacept–treated group, primarily driven by a lower
number of infections in the former group. Serious
infections were reported in 5 patients (0.7%) in the SC
abatacept–treated group and 10 patients (1.4%) in the
IV abatacept–treated group. The proportion of serious
infections with IV abatacept was comparable to previ-
ously reported rates in a similar patient population (24),
while the proportion of serious infections with SC
abatacept was toward the lower end of previous obser-
vations. Furthermore, no opportunistic infections, in-
cluding TB, were reported during the treatment period;
this is consistent with the overall low rates reported in
multiple phase III studies of IV abatacept in a similar
population (6,7,24). A high proportion of patients com-
pleted the study, and numbers were comparable be-
tween treatment arms. The proportion of patients who
discontinued due to AEs was low, and 1% in each
group discontinued due to lack of efficacy.
Important considerations with SC administration
of biologic agents are injection site reactions and toler-
ability. SC drug administration can be associated with
adverse reactions at the site of injection, particularly
injection site pain (31,32). In this study the overall
incidence of injection site reactions with SC abatacept
was low (3%) and consistent with previous reports
(11–14), indicating that the SC formulation is not asso-
ciated with significant AEs at the injection site. This is
further supported by the demonstration that the injec-
tion site reactions were comparable between patients
receiving SC abatacept and those receiving SC placebo
in the IV abatacept–treated group, with injection site
pain reported in 1 and 4 patients, respectively. The
incidence of injection site reactions observed with SC
administration of etanercept plus MTX has been re-
ported to range from 6.5% over 3 months to 10% over
1 year (33–35), and rates with adalimumab plus MTX in
the range of 19.5–26.1% over 1 year have been observed
(31,36).
Another potential challenge associated with SC
protein therapeutics is the development of immuno-
genicity, which can result in a diminished clinical re-
sponse in patients with RA (37,38). In this 6-month
study of patients with an inadequate response to MTX,
the proportion of patients with abatacept-induced anti-
bodies was 1% in the SC abatacept–treated group and
2% in the IV abatacept–treated group. This low rate of
immunogenicity is consistent with that reported in other
SC abatacept clinical trials, in patients with up to 18
months of exposure to abatacept, administered as mono-
therapy or with concomitant MTX (11–14). The results
are also consistent with reported immunogenicity rates
from clinical trials using IV abatacept (5,9,39). Impor-
tantly, no effect on efficacy or safety was observed in the
few patients who developed antibody responses to abata-
cept.
Interpretation of these results should take into
consideration the limitations of the study, and the safety
results should be interpreted in the context of the
6-month study duration. Approximately 5% of patients
in each treatment group had at least 1 protocol devia-
tion, mostly related to disease activity at entry or
concomitant steroid use. However, comparable efficacy
benefits were observed regardless of whether the popu-
lation was analyzed on a per-protocol or ITT basis,
suggesting that the results of this study are robust. In
addition, although patients were permitted up to 2
courses of high-dose corticosteroids, the proportions of
patients receiving these were low and comparable be-
tween treatment groups, so this was not likely to have
affected study outcomes.
Due to the nature of the trial, all participants
received active treatment; it is possible that this could
affect the study findings by introducing an element of
patient or assessor bias. However, any effect would apply
across both treatment arms and would therefore be
unlikely to affect comparisons between SC and IV
abatacept–treated groups.
In summary, SC abatacept demonstrates efficacy
and safety that are comparable and consistent with the
established IV abatacept profile, including low immuno-
genicity and high retention rates. Importantly, injection
site reactions with the SC formulation were infrequent
and mild. These data support the use of abatacept for SC
2862 GENOVESE ET ALadministration, providing an additional and beneficial
treatment option for patients with RA.
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